Provided by Tiger Trade Technology Pte. Ltd.

Summit Therapeutics PLC

16.91
+0.52003.17%
Post-market: 16.920.0100+0.06%19:58 EDT
Volume:13.06M
Turnover:224.22M
Market Cap:13.49B
PE:-15.13
High:17.72
Open:16.59
Low:16.17
Close:16.39
52wk High:29.23
52wk Low:12.07
Shares:797.75M
Float Shares:152.34M
Volume Ratio:1.41
T/O Rate:8.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1177
EPS(LYR):-1.4439
ROE:-192.50%
ROA:-101.61%
PB:21.41
PE(LYR):-11.71

Loading ...

Summit Therapeutics Q2 FY26 Net Loss Narrows to $215.7 Million

Reuters
·
Jul 24

Summit Therapeutics Q2 Net Income USD -215.7 Million

Reuters
·
Jul 24

Summit Therapeutics Q2 EPS USD -0.28

THOMSON REUTERS
·
Jul 24

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026

THOMSON REUTERS
·
Jul 24

Analysts Have Conflicting Sentiments on These Healthcare Companies: Summit Therapeutics (SMMT), Molina Healthcare (MOH) and Johnson & Johnson (JNJ)

TIPRANKS
·
Jul 23

European Car Market Stages Robust Recovery with Strongest Monthly Sales Gain in Nearly Three Years, Electric Vehicles Provide Critical Boost

Stock News
·
Jul 23

UK’s EV battery sector moves to industrial scale, but can it build a midstream?: Battery Cells & Systems Expo

Fastmarkets
·
Jul 23

Arcus Biosciences, Summit Therapeutics Team up to Test Casdatifan-ivonescimab Combo in Kidney Cancer

Reuters
·
Jul 23

Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer

THOMSON REUTERS
·
Jul 23

Summit Gains on Updated Trial Data for Experimental Lung Cancer Drug

Reuters
·
Jul 22

Summit Therapeutics Announces Availability of Ivonescimab Harmoni Trial Update Press Release

Reuters
·
Jul 22

Summit Therapeutics - FDA Accepts Bla for Ivonescimab; Pdufa Date November 14, 2026

THOMSON REUTERS
·
Jul 22

Summit Therapeutics - Phase Iii Harmoni Study Shows Statistically Significant Pfs Benefit

THOMSON REUTERS
·
Jul 22

Summit Therapeutics - Ivonescimab Continues to Show Acceptable Safety Profile; no New Safety Signals

THOMSON REUTERS
·
Jul 22

Summit Therapeutics - Ivonescimab Plus Chemotherapy Shows Positive Os Trend in Asian and Western Patients

THOMSON REUTERS
·
Jul 22

Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase Iii Harmoni Study

THOMSON REUTERS
·
Jul 22

Analysts Are Bullish on These Healthcare Stocks: Damora Therapeutics (DMRA), Summit Therapeutics (SMMT)

TIPRANKS
·
Jul 22

What Comes After Merck's Keytruda? the Race for the Next Standard Cancer Treatment.

Dow Jones
·
Jul 20

Earning Preview: Summit Therapeutics PLC this quarter’s revenue is expected to increase by 0%, and institutional views are bullish

Earnings Agent
·
Jul 17

Kalshi to Allow Bets on Clinical Trials, FDA Decisions

Reuters
·
Jul 16